JO
CMPX icon

John Overdeck’s Compass Therapeutics CMPX Stock Holding History

John Overdeck’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$701K Buy
320,312
+287,212
+868% +$848K ﹤0.01% 3895
2026
Q1 		$175K Buy
+33,100
New +$191K ﹤0.01% 4304
2025
Q3 		– Sell
-16,097
Closed -$41.9K – 3684
2025
Q2 		$41.9K Sell
16,097
-35,142
-69% -$72.5K ﹤0.01% 3084
2025
Q1 		$97.4K Sell
51,239
-93,999
-65% -$250K ﹤0.01% 2969
2024
Q4 		$211K Sell
145,238
-48,021
-25% -$79.8K ﹤0.01% 2863
2024
Q3 		$356K Sell
193,259
-21,791
-10% -$27.2K ﹤0.01% 2608
2024
Q2 		$215K Buy
215,050
+73,408
+52% +$107K ﹤0.01% 2711
2024
Q1 		$280K Sell
141,642
-51,058
-26% -$88.2K ﹤0.01% 2587
2023
Q4 		$301K Buy
192,700
+167,000
+650% +$289K ﹤0.01% 2695
2023
Q3 		$50.6K Buy
+25,700
New +$63.5K ﹤0.01% 2813
2023
Q2 		– Sell
-15,222
Closed -$49.8K – 3049
2023
Q1 		$49.8K Buy
+15,222
New +$59.8K ﹤0.01% 2754

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

John Overdeck's CMPX Position: Q2 2026 in Review

John Overdeck increased its Compass Therapeutics (CMPX) stake by 868% in Q2 2026, buying an estimated $848K and bringing the position to 320,312 shares worth $701K. The position accounts for ﹤0.01% of the portfolio, ranked #3895.

John Overdeck first reported a position in CMPX in Q1 2023 and has held it in 11 quarters since. 213 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • John Overdeck held 320,312 shares of Compass Therapeutics worth $701K as of Q2 2026.
  • John Overdeck bought 287,212 Compass Therapeutics shares in Q2 2026, an estimated $848K.
  • Compass Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3895 holding.
  • John Overdeck first reported a position in Compass Therapeutics in Q1 2023 and has held it in 11 quarters since.
  • 213 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.